Browse

Sirolimus and Metformin Synergistically Inhibits Colon Cancer In vitro and In vivo
생체 외 및 생체 내 실험을 통한 시롤리무스와 메트포민의 대장암 억제 시너지 효과

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
나디아르
Advisor
이광웅
Major
의과대학 의학과
Issue Date
2018-02
Publisher
서울대학교 대학원
Keywords
Liver transplantationimmunosuppressionde novo colon cancermetformin
Description
학위논문 (박사)-- 서울대학교 대학원 : 의과대학 의학과, 2018. 2. 이광웅.
Abstract
We estimated the effect of various immunosuppressants (IS) and metformin to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620 and HCT116) were used in in vitro studies. HT29 was also used in BALB/c-nude mice animal models. Following groups were used in both in vitro and in vivo studies: sirolimus (S), tacrolimus (T), cyclosporin A (CsA), metformin (M), metformin/sirolimus (Met/S), metformin/tacrolimus (Met/T), and metformin/cyclosporin A (Met/CsA). 3-(4 5-Dimethylthiazol-2-yl)-2 5-diphenyltetrazolium bromide (MTT) assay was performed and Western blot analyses were performed for mTOR pathway proteins, apoptosis proteins, and EMT proteins. Tumor volume was measured for 4 weeks after inoculation. MTT-assay revealed significant cell viability inhibition in all three colon cancer cell lines in groups of S, M, and Met/S. Of note, group Met/S showed synergistic effect compare to M or S group. Western blot analysis showed significant low levels of all investigated proteins in groups of S and Met/S in both in vitro and in vivo experiment. Tumor growth was significantly inhibited only in the Met/S group. Combination of Met and S showed the most potent inhibition in all colon cancer cell lines. This finding might have application for de novo colon cancer.
Language
English
URI
http://hdl.handle.net/10371/141035
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Ph.D. / Sc.D._의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse